Cancer Investigation 2013-03-01

Phase II trial assessing granulocyte-macrophage-colony stimulating factor, ketoconazole plus mitoxantrone in metastatic castration-resistant prostate cancer progressing after docetaxel treatments.

Robert J Amato, Somyata Saxena, Mika Stepankiw

文献索引：Cancer Invest. 31(3) , 177-82, (2013)

全文：HTML全文

摘要

This study evaluated objective response and safety for the combination of granulocyte macrophage-colony stimulating factor (GM-CSF), ketoconazole, and mitoxantrone in castration-resistant prostate cancer (CRPC) patients who previously failed docetaxel-based chemotherapy.Treatment consisted of 400 mg TID ketoconazole, 12 mg/m(2) mitoxantrone every 3 weeks, and 250 μg/m(2) GM-CSF.Twenty-nine patients were evaluable for response. Median overall survival (OS) for all patients was 18.03 months. Patients with a higher PSA decrease experienced an increased OS and progression-free survival (PFS).This combination demonstrated significant antitumor activity with reversible toxicity in CRPC patients who previously failed docetaxel-based therapy.

相关化合物

  • 酮康唑
  • 盐酸米托蒽醌

相关文献：

Diclofenac toxicity in human intestine ex vivo is not related to the formation of intestinal metabolites.

2015-01-01

[Arch. Toxicol. 89(1) , 107-19, (2015)]

Neuropharmacokinetics of two investigational compounds in rats: divergent temporal profiles in the brain and cerebrospinal fluid.

2014-10-15

[Biochem. Pharmacol. 91(4) , 543-51, (2014)]

Activation of the pleiotropic drug resistance pathway can promote mitochondrial DNA retention by fusion-defective mitochondria in Saccharomyces cerevisiae.

2014-07-01

[G3 (Bethesda) 4(7) , 1247-58, (2014)]

Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.

2010-01-01

[Chem. Res. Toxicol. 23 , 171-83, (2010)]

Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

2011-12-01

[J. Sci. Ind. Res. 65(10) , 808, (2006)]

更多文献...